{"id":9786,"date":"2020-07-27T21:45:45","date_gmt":"2020-07-27T21:45:45","guid":{"rendered":"https:\/\/bengalnewstimes.com\/?p=9786"},"modified":"2020-07-27T21:45:45","modified_gmt":"2020-07-27T21:45:45","slug":"russia-offers-to-supply-anti-covid-19-drugs","status":"publish","type":"post","link":"https:\/\/bengalnewstimes.com\/?p=9786","title":{"rendered":"Russia offers to supply anti-COVID-19 drugs"},"content":{"rendered":"

<\/p>\n

\n

Russia is scouting for partners in India for supplying three anti-COVID-19<\/a> drugs manufactured indigenously. They had yielded positive results there.<\/p>\n

Favipiravir (trade name Avifavir); Olokizumab (trade name Artlegia); and Levilimab (trade name: Ilsira) are the drugs it wants to supply.<\/p>\n

Developed locally<\/h2>\n

According to the Pharmaceuticals Export Promotion Council of India, Russia has domestically developed a few drugs and registered a number of foreign drugs for treatment of COVID- 19.<\/p>\n

\u201cThe Russian Ministry of Health and its industry has offered to supply three indigenously manufactured anti-COVID-19 drugs, showing positive results in Russia, to Indian companies,\u201d Pharmexcil Director General Ravi Udaya Bhaskar said.<\/p>\n

Sharing details of the three drugs and coordinates of entities manufacturing them in Russia, a Pharmexcil communication said those having \u201csubstantive commercial interest are requested to approach the contacts provided for each drug.\u201d<\/p>\n

Import of any drug into India has to be in compliance with the provisions of the Drugs & Cosmetics Act, 1940 & Rules 1945, according to Mr. Ravi Udaya Bhaskar said.<\/p>\n<\/div>\n

\n
\n
\n
\n
\n

You have reached your limit for free articles this month.<\/p>\n

To get full access, please subscribe. <\/p>\n

Already have an account ? Sign in<\/a>\n<\/p>\n<\/div>\n<\/div>\n<\/div>\n

Show Less Plan <\/p>\n<\/div>\n

\n

Subscription Benefits Include<\/h4>\n
\n
\n
\n<\/p>\n
\n
Today’s Paper<\/h6>\n

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n<\/p>\n
\n
Faster pages<\/h6>\n

Move smoothly between articles as our pages load instantly.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n<\/p>\n
\n
Unlimited Access<\/h6>\n

Enjoy reading as many articles as you wish without any limitations.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n<\/p>\n
\n
Dashboard<\/h6>\n

A one-stop-shop for seeing the latest updates, and managing your preferences.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n<\/p>\n
\n
Personalised recommendations<\/h6>\n

A select list of articles that match your interests and tastes.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n<\/p>\n
\n
Briefing<\/h6>\n

We brief you on the latest and most important developments, three times a day.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n

\n*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.\n<\/p>\n<\/div>\n<\/div>\n

\n
\n

A letter from the Editor<\/h3>\n\n

Dear subscriber,<\/p>\n

Thank you!<\/p>\n

Your support for our journalism is invaluable. It\u2019s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.<\/p>\n

The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.<\/p>\n

We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.<\/p>\n

Suresh Nambath<\/p>\n<\/div>\n<\/div>\n

Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Russia is scouting for partners in India for supplying three anti-COVID-19 drugs manufactured indigenously. They had yielded positive results there. Favipiravir (trade name Avifavir); Olokizumab (trade name Artlegia); and Levilimab (trade name: Ilsira) are the drugs it wants to supply. Developed locally According to the Pharmaceuticals Export Promotion Council of […]<\/p>\n","protected":false},"author":1,"featured_media":9787,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"spay_email":"","footnotes":""},"categories":[36],"tags":[],"class_list":["post-9786","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-banking-business"],"jetpack_featured_media_url":"https:\/\/bengalnewstimes.com\/wp-content\/uploads\/2020\/07\/20THFAVIPIRAVIR.jpeg","_links":{"self":[{"href":"https:\/\/bengalnewstimes.com\/index.php?rest_route=\/wp\/v2\/posts\/9786","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bengalnewstimes.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bengalnewstimes.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bengalnewstimes.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bengalnewstimes.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9786"}],"version-history":[{"count":0,"href":"https:\/\/bengalnewstimes.com\/index.php?rest_route=\/wp\/v2\/posts\/9786\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bengalnewstimes.com\/index.php?rest_route=\/wp\/v2\/media\/9787"}],"wp:attachment":[{"href":"https:\/\/bengalnewstimes.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9786"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bengalnewstimes.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9786"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bengalnewstimes.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}